A Catalog of All Known FAAH and MAGL Inhibitors and Their Chemical Characteristics
The range of available FAAH inhibitors far exceeded MAGL inhibitors, with most MAGL inhibitors lacking selectivity, highlighting a gap in the endocannabinoid pharmacology toolkit.
Quick Facts
What This Study Found
This review cataloged and compared all known synthetic inhibitors of FAAH and MAGL, the two primary enzymes that break down the endocannabinoids anandamide and 2-AG.
FAAH inhibitors fell into two groups: substrate-inspired compounds (mimicking the fatty acid chains of anandamide, oleamide, or PEA) and structurally novel compounds (carbamates, oxazolopyridines, imidazolidines, and even some NSAIDs). The substrate-inspired group was extensive and included highly selective compounds.
MAGL inhibitors were far fewer in number and most lacked selectivity, meaning they also inhibited other enzymes. This disparity reflected the earlier characterization of FAAH and the greater research attention it had received.
The review provided detailed comparisons of synthetic pathways, potencies, selectivities, and mechanisms of inhibition to facilitate research tool selection.
Key Numbers
FAAH inhibitor families: substrate-inspired (arachidonoyl, oleoyl, palmitoyl chains) and novel (carbamates, oxazolopyridines, etc.). MAGL inhibitors: few members, most lacking selectivity. FAAH was cloned nearly simultaneously with MAGL but received far more pharmacological attention.
How They Did This
Comprehensive review of published literature on FAAH and MAGL inhibitor chemistry, covering synthetic pathways, potencies (IC50 values), selectivities, and mechanisms of action for all known inhibitor families.
Why This Research Matters
Selective enzyme inhibitors are essential tools for understanding endocannabinoid function and for developing therapeutics. This catalog highlighted the urgent need for better MAGL inhibitors, a gap that has since been addressed.
The Bigger Picture
This review influenced the direction of medicinal chemistry efforts in the endocannabinoid field. The identified gap in MAGL inhibitors was subsequently addressed, leading to selective MAGL inhibitors that are now in clinical trials.
What This Study Doesn't Tell Us
As a chemistry-focused review, it did not cover in vivo efficacy or safety in detail. The field was evolving rapidly, and new inhibitors were being developed. Some potency comparisons across studies using different assay conditions must be interpreted cautiously.
Questions This Raises
- ?Can highly selective MAGL inhibitors be developed for clinical use?
- ?How do the therapeutic profiles of FAAH vs. MAGL inhibition differ?
Trust & Context
- Key Stat:
- FAAH inhibitors were extensive and selective; MAGL inhibitors were few and non-selective
- Evidence Grade:
- This is a comprehensive medicinal chemistry review providing a thorough catalog of the field's chemical tools, with moderate evidence quality for the comparisons made.
- Study Age:
- Published in 2008. Since then, highly selective MAGL inhibitors have been developed and some have entered clinical trials.
- Original Title:
- Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
- Published In:
- Current topics in medicinal chemistry, 8(3), 247-67 (2008)
- Authors:
- Vandevoorde, Séverine
- Database ID:
- RTHC-00335
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does it matter which enzyme is blocked?
FAAH mainly breaks down anandamide, while MAGL mainly breaks down 2-AG. These endocannabinoids have somewhat different effects, so selectively blocking one versus the other can produce different therapeutic profiles.
Could these compounds become medicines?
Some FAAH inhibitors have entered clinical trials, and selective MAGL inhibitors developed after this review are also being tested. The goal is to boost the body's own endocannabinoids for therapeutic effect while avoiding the broad effects of administering THC or similar compounds.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00335APA
Vandevoorde, Séverine. (2008). Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.. Current topics in medicinal chemistry, 8(3), 247-67.
MLA
Vandevoorde, Séverine. "Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.." Current topics in medicinal chemistry, 2008.
RethinkTHC
RethinkTHC Research Database. "Overview of the chemical families of fatty acid amide hydrol..." RTHC-00335. Retrieved from https://rethinkthc.com/research/vandevoorde-2008-overview-of-the-chemical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.